| GJB1 | |||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| |||||||||||||||||||||||||||||||||||||||||||||||||||
| Identifiers | |||||||||||||||||||||||||||||||||||||||||||||||||||
| Aliases | GJB1, CMTX, CMTX1, CX32, gap junction protein beta 1 | ||||||||||||||||||||||||||||||||||||||||||||||||||
| External IDs | OMIM:304040;MGI:95719;HomoloGene:137;GeneCards:GJB1;OMA:GJB1 - orthologs | ||||||||||||||||||||||||||||||||||||||||||||||||||
| |||||||||||||||||||||||||||||||||||||||||||||||||||
| |||||||||||||||||||||||||||||||||||||||||||||||||||
| |||||||||||||||||||||||||||||||||||||||||||||||||||
| |||||||||||||||||||||||||||||||||||||||||||||||||||
| |||||||||||||||||||||||||||||||||||||||||||||||||||
| Wikidata | |||||||||||||||||||||||||||||||||||||||||||||||||||
| |||||||||||||||||||||||||||||||||||||||||||||||||||
Gap junction beta-1 protein (GJB1), also known asconnexin 32 (Cx32), is atransmembrane protein that in humans is encoded by theGJB1gene.[a][5] Gap junction beta-1 protein is a member of thegap junctionconnexin family of proteins that regulates and controls the transfer of communication signals acrosscell membranes, primarily in theliver andperipheral nervous system.[6] However, the protein is expressed in multiple organs, including in oligodendrocytes in the central nervous system.[7]
Mutations of theGJB1 gene affecting the signalling of and trafficking through gap junctions, resulting in an inherited peripheral neuropathy called X-linkedCharcot-Marie-Tooth Disease. Complications include thedemyelination ofoligodendrocytes andSchwann cells, causing delayed transmission rates of nerve communication in the peripheral nervous system, due to irregularities in the normal function of the cells. This condition leads to a number of symptoms, most commonly muscle weakness and sensory problems in the outer extremities of the limbs. As a result,muscle atrophy and soft tissue injuries due to delayed nerve transmission can occur. In males, due to the hemizygousity of the X-chromosome, the symptoms and issues surrounding X-linked Charcot-Marie-Tooth disease are more prevalent.[8]
Connexins are membrane-spanning proteins that assemble to form gap junction channels that facilitate the transfer of ions and small molecules between cells.[9] For a general discussion of connexin proteins, seeGJB2.[10] In Schwann cells, GJB1 also forms channels that facilitate transfers between layers of the myelin.[11]
In melanocytic cellsGJB1 gene expression may be regulated byMITF.[12]
The gene that encodes the human GJB1 protein is found on theX chromosome, on the long arm at position q13.1, in interval 8, from base pair 71,215,212 to base pair 71,225,215.[5][9]
Approximately four hundredmutations within theGJB1 gene have been identified as causing type X Charcot-Marie-Tooth disease, and it is the only gene known to be associated with this disease.[13][14] The majority of these mutations only change a single amino acid within the protein chain, which result in a different protein being produced. Mutations within theGJB1 gene consist of novel,missense, double-missense, amino acid deletion,nonsense,frameshift, and in-frame deletions/insertions.[6][8][9][15] These mutations most commonly result in proteins that work incorrectly, less effectively, degrade faster, are not present in adequate numbers or may not function at all.
TheGJB1 gene is approximately 10kb in length, with one codingexon and three non-coding exons. GJB1 is agap junction, beta 1 protein also identified as connexin 32, with 238amino acids.[8] This protein contains four transmembrane domains, which when assembled form gap junctions. Each of these gap junctions consist of two hemichannels (connexions), which in turn consist of sixconnexin molecules (gap junction trans-membrane proteins).,[8][9] A picture of a connexin and its connexons, showing the two hemichannels, is available here:https://commons.wikimedia.org/wiki/File:Connexon_and_connexin_structure.svg. This enables communication betweenSchwann cellnuclei andaxons through a radial diffusion pathway.[8] As noted above, channels also form between layers of myelin.[16]
GJB1 functions as a radial diffusion pathway, allowing the communication and diffusion of nutrients, ions and small molecules between cells, and between layers of myelin.[8] The GJB1 protein is found in a number of organs, including theliver,kidney,pancreas andnervous system.[6][9] In normal circumstances this protein is located in the cellmembrane ofSchwann cells andoligodendrocytes, specialised cells of the nervous system.[9][17] These cells typically encapsulate nerves and are involved in the assembly and preservation ofmyelin, which serves to ensure reliable and rapid transmission of nerve signals.[9][17] Typically the GJB1 protein forms channels between cells as well as through myelin to the internal Schwann cell or oligodendrocyte, allowing effective transportation and communication.[9][17]
Mutations in theGJB1 gene can lead to a variety of changes in the Connexin 32 protein or its expression, as compared to the wild type gene. Pathogenic mutations in the gene affect signalling and trafficking of small molecules through gap junctions, resulting in disease - most notably an inherited peripheral neuropathy known as Charcot-Marie-Tooth disease, also often referred to as CMT. Despite the name, CMT does not affect the teeth; the word "tooth" refers to the name of one of the doctors who were important to its discovery. BecauseGJB1 is located on the X chromosome,GJB1 disease is a type of "X-linked" CMT. Multiple X-linked CMTs have now been identified, andGJB1 disease is referred to as CMT1X or CMTX1.[18] The disease process involvesdemyelination of nerves due to impact on theSchwann cells, causing delayed transmission rates of nerve communication in the peripheral nervous system, due to irregularities in the normal function of the cells. In addition, impact on axons has been noted, While it was originally believed that axon impact was secondary to demyelination, findings in mice suggest that axon slowing may occur independent from and precede demyelination in CMT1X, due to disturbed signalling between axons and glia as well as disturbances in glial support to axons.[19]
Unlike many other types of CMT, CMT1X is known to cause effects in the central nervous system ("CNS") as well as the peripheral nervous system.[13] However, it is believed that whether or not an individual experiences CNS effects may depend upon the specific mutation involved, and the more precise shape and function of the mutant protein in question, as some mutant GJB1 proteins have much more functionality than others.[20]
This condition leads to a number of symptoms, most commonly muscle weakness and sensory problems in the outer extremities of the limbs. As a result,muscle atrophy and soft tissue injuries due to delayed nerve transmission can occur. In males, due to the hemizygosity of the X-chromosome, the symptoms and issues surrounding X-linkedCharcot-Marie-Tooth disease are more prevalent.[8]
Approximately four hundred mutations of theGJB1 gene have been identified in people with X-linked Charcot-Marie-Tooth disease (CMTX).[17] CMTX is predominantly classified with symptoms related to muscle weakness and sensory problems, especially in the outer extremities of the limbs.[9] CMTX is the second most common type of CMT (about 10% of all patients) and is transmitted as anx-linkeddominant trait.[8] It is categorised by the lack of male-to-male transmission of the mutatedGJB1 gene and the differences in severity betweenheterozygous women andhemizygous men, with the later being more severely affected.[13]
Most of the mutations of theGJB1 gene switch or change a singleamino acid in the gap junction (connexin-32) protein, although some may result in a protein of irregular size.[8][13][15][17] Some of these mutations also causehearing loss in patients with CMTX.[17] Currently it is unknown how the mutations of theGJB1 gene lead to these specific features of Charcot-Marie-Tooth disease, however it is theorised that the cause is due to thedemyelination of nerve cells.[17] As a result, transmission rates of nerve communication in theperipheral nervous system are delayed, which in turn would cause irregularities in the normal function ofSchwann cells.[17]
Whilst CMTX is more commonly known to affect the peripheral nervous system some cases have been reported in which there is evidence of demyelination of thecentral nervous system.[6][17] These abnormalities whilst not presenting any symptoms were identified throughnerve impulse and imaging studies, and are believed to also be caused through mutations on theGJB1 gene.[17]
Historically CMTX could only be diagnosed through symptoms or measurement of the speed of nerve impulses. With the creation ofgenetic testing, 90% of CMTX cases are now diagnosed using the mutations of theGJB1 (Cx32) gene.[13] Thegenetic screening of families has also become common after the diagnosis of CMTX in a patient, to further identify other family members that may be suffering from the disease. This screening is also used systematically by researchers to identify new mutations within the gene.[6][14][15]
Currently CMTX is an incurable condition, instead patients are evaluated and treated for symptoms caused by the disease. Treatment is limited to rehabilitative therapy, use of assistive devices such asorthoses and in some cases surgical treatment of skeletal deformities and soft-tissue abnormalities.[13] Surgical treatment most commonly includesosteotomies, soft-tissue surgery (includingtendon transfers) and/or joint fusions.[13]
Due to the nature of inheritance of CMTX, affected males will pass theGJB1 gene mutation to all female children and none of their male children, whilst females who are carriers will have a 50% chance of passing on the mutation to each of their offspring.[13] With the development of genetic testing, it is possible to perform bothprenatal andpre-implantation testing elected by the patient, when their type of mutation has been identified.[13] Results from genetic testing can then be used to prevent the transmission of this disease to their offspring.
